Invasive pneumococcal disease in children under 60 months before and after availability of 13-valent conjugate vaccine
Copyright © 2021 Asociación Española de Pediatría. Publicado por Elsevier España, S.L.U. All rights reserved..
BACKGROUND: Invasive pneumococcal disease (IPD) is the most important bacterial infection in young children, and the introduction of pneumococcal conjugate vaccines has changed its presentation. This study compared the incidence, characteristics and serotype distribution of IPD before and after the introduction of the pneumococcal conjugate vaccine (PCV13).
METHODS: Prospective enrolment of patients with IPD aged less than 60 months and admitted to either of 2 tertiary care hospitals between January 2007 and December 2009 (pre-PCV13 period) and January 2012 and June-2016 (PCV13 period).
RESULTS: We identified 493 cases, 319 in the pre-PCV13 period and 174 in the PCV13 period. The incidence of IPD decreased from 89.7 to 34.4 cases per 100,000 population (-62%; P<.001). This decrease was observed in all forms of disease except necrotising pneumonia (increase from 0.8 to 3.7 cases/100,000 population). There was a significant reduction in all serotypes included in the PCV13 and not included in the PCV7. We did not find significant differences in length of stay, mortality or the frequency of sequelae between both periods, but in the PCV13 period, the length of stay in the paediatric intensive care unit and the duration of mechanical ventilation were longer (P=.00). The incidence of serotype 3 decreased from 10.4 to 6.9 cases per 100,000 population, although it was the serotype involved most frequently in patients with severe disease.
CONCLUSIONS: After the introduction of the PCV13, there has been a significant decrease in IPD cases. Serotype 3 continues to be an important cause of severe IPD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2021 |
|---|---|
| Enthalten in: |
Anales de pediatria - (2021) vom: 30. Juni |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Enfermedad neumocócica invasiva en niños menores de 60 meses, antes y después de la introducción de la vacuna conjugada 13-valente |
|---|
| Beteiligte Personen: |
Martínez-Osorio, Johanna [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Enfermedad neumocócica invasiva |
|---|
| Anmerkungen: |
Date Revised 20.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.anpedi.2021.05.018 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327643382 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327643382 | ||
| 003 | DE-627 | ||
| 005 | 20240220231824.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.1016/j.anpedi.2021.05.018 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1300.xml |
| 035 | |a (DE-627)NLM327643382 | ||
| 035 | |a (NLM)34217675 | ||
| 035 | |a (PII)S1695-4033(21)00206-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Martínez-Osorio, Johanna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Invasive pneumococcal disease in children under 60 months before and after availability of 13-valent conjugate vaccine |
| 246 | 3 | 3 | |a Enfermedad neumocócica invasiva en niños menores de 60 meses, antes y después de la introducción de la vacuna conjugada 13-valente |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2021 Asociación Española de Pediatría. Publicado por Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a BACKGROUND: Invasive pneumococcal disease (IPD) is the most important bacterial infection in young children, and the introduction of pneumococcal conjugate vaccines has changed its presentation. This study compared the incidence, characteristics and serotype distribution of IPD before and after the introduction of the pneumococcal conjugate vaccine (PCV13) | ||
| 520 | |a METHODS: Prospective enrolment of patients with IPD aged less than 60 months and admitted to either of 2 tertiary care hospitals between January 2007 and December 2009 (pre-PCV13 period) and January 2012 and June-2016 (PCV13 period) | ||
| 520 | |a RESULTS: We identified 493 cases, 319 in the pre-PCV13 period and 174 in the PCV13 period. The incidence of IPD decreased from 89.7 to 34.4 cases per 100,000 population (-62%; P<.001). This decrease was observed in all forms of disease except necrotising pneumonia (increase from 0.8 to 3.7 cases/100,000 population). There was a significant reduction in all serotypes included in the PCV13 and not included in the PCV7. We did not find significant differences in length of stay, mortality or the frequency of sequelae between both periods, but in the PCV13 period, the length of stay in the paediatric intensive care unit and the duration of mechanical ventilation were longer (P=.00). The incidence of serotype 3 decreased from 10.4 to 6.9 cases per 100,000 population, although it was the serotype involved most frequently in patients with severe disease | ||
| 520 | |a CONCLUSIONS: After the introduction of the PCV13, there has been a significant decrease in IPD cases. Serotype 3 continues to be an important cause of severe IPD | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Enfermedad neumocócica invasiva | |
| 650 | 4 | |a Invasive pneumococcal disease | |
| 650 | 4 | |a Pneumococcal conjugate vaccine | |
| 650 | 4 | |a Streptococcus pneumoniae | |
| 650 | 4 | |a VNC | |
| 650 | 4 | |a Vacuna antineumocócica conjugada | |
| 700 | 1 | |a García-García, Juan José |e verfasserin |4 aut | |
| 700 | 1 | |a Moraga-Llop, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Díaz, Alvaro |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández, Sergi |e verfasserin |4 aut | |
| 700 | 1 | |a Solé-Ribalta, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a González-Peris, Sebastià |e verfasserin |4 aut | |
| 700 | 1 | |a Izquierdo, Conchita |e verfasserin |4 aut | |
| 700 | 1 | |a Esteva, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Codina, Gemma |e verfasserin |4 aut | |
| 700 | 1 | |a Planes, Ana María |e verfasserin |4 aut | |
| 700 | 1 | |a Uriona, Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a Campins, Magda |e verfasserin |4 aut | |
| 700 | 1 | |a Ciruela, Pilar |e verfasserin |4 aut | |
| 700 | 1 | |a Salleras, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Domínguez, Ángela |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz-Almagro, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a de Sevilla, Mariona F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anales de pediatria |d 2010 |g (2021) vom: 30. Juni |w (DE-627)NLM19488628X |x 2341-2879 |7 nnns |
| 773 | 1 | 8 | |g year:2021 |g day:30 |g month:06 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.anpedi.2021.05.018 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 30 |c 06 | ||